Skip to content

Observation of macular blood flow density and changes of cytokines in anterior chamber water after treatment of diabetes macular edema with Conbercept combined with dexamethasone vitreous implant

Observation of macular blood flow density and changes of cytokines in anterior chamber water after treatment of diabetes macular edema with Conbercept combined with dexamethasone vitreous implant

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084218
Enrollment
Unknown
Registered
2024-05-13
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic macular edema (DME)

Interventions

Experimental group:3 times anti VEGF+1 time Ozurdex+1 time anti VEG
Control group:3 times anti VEGF+1 time anti VEGF+1 time anti VEGF

Sponsors

Inner Mongolia Chaoju Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) The patient is informed of this study and has signed an informed consent form, willing to execute it in accordance with the requirements of the clinical trial protocol; (2) OCTA examination showed macular edema, with a thickness of = 300 within a range of 1 mm in diameter in the central area of the macula measured µ m. Record blood flow density; (3) Treatment without macular grid like photocoagulation, intravitreal injection of triamcinolone acetonide, intravitreal injection of anti VEGF drugs, etc; (4) Age>18 years old.

Exclusion criteria

Exclusion criteria: (1) Refractive interstitial opacity affects fundus observers; (2) Patients with combined eye diseases such as glaucoma, uveitis, and optic nerve disease; (3) Poor overall condition, combined with severe cardiovascular, cerebrovascular, liver, and hematopoietic system diseases, as well as severe life-threatening primary diseases and psychiatric patients; (4) Patients with unstable myocardial infarction, cerebral infarction, and other contraindications for intravitreal anti VEFG injection; (5) Participants in clinical trials of other drugs; (6) Individuals who are unable to cooperate in completing various examinations due to age, illness, or other reasons.

Design outcomes

Primary

MeasureTime frame
General patient information;Best Corrected Visual Acuity (BCVA);Central Macular Thickness (CMT);DRSS score;Biochemical Indicators;Area of FAZ;Perimeter of FAZ;Complication;IL-6, IL-8, IL-10, VEGF, PFGF in anterior aqueous humor;

Secondary

MeasureTime frame
Intra-Ocular pressure (IOP);deep blood flow density;superficial blood flow density;

Countries

China

Contacts

Public ContactGong Hui

Inner Mongolia Chaoju Eye Hospital

1010288685@qq.com+86 153 9116 9866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026